跳至主要内容
临床试验/ISRCTN46911260
ISRCTN46911260已完成3 期

Vascular Augmentation of Late-life Unremitted Depression: a randomised study

Gateshead Health NHS Foundation Trust (UK)0 个研究点目标入组 8 人开始时间: 2012年1月31日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •1. Age 50 years and over
  • •2. Clinically significant (unremitted) vascular depression, as defined above
  • •3. Mini mental state examination (MMSE) >23
  • •4. Medically stable
  • •5. BP < 150/90 (QoF Audit standard)
  • •6. Patient has provided written informed consent for participation in the study prior to any study specific procedures. ; Lower Age Limit 50 years

排除标准

  • •1. Taking a calcium channel blocker
  • •2. Clinical evidence of dementia
  • •3. History or clinical evidence of stroke
  • •4. History of bipolar or psychotic disorder
  • •5. Significant suicide risk
  • •6. Known hypersensitivity to amlodipine or any other calcium channel blocker
  • •7. Severe renal or hepatic impairment
  • •8. Pregnancy, or women planning to become pregnant within next 12 months, or women who are breast feeding
  • •9. Use of other investigational study drugs within 30 days prior to study entry (defined as date of randomisation into study)
  • •10. Previous participation in this study
  • •11. Presence of cardiac pace-maker or other contraindications to (only applies to those consenting to MRI sub-study)

研究者

发起方
Gateshead Health NHS Foundation Trust (UK)

相似试验